rencofilstat, 75 mg + rencofilstat, 150mg + rencofilstat, 225 mg

Phase 2Completed

0 views this week 0 watching💤 Quiet

Interest: 25/100

Hype Score

Development Stage

✓

Pre-clinical

✓

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

NASH With Fibrosis

Conditions

NASH With Fibrosis

Trial Timeline

Mar 15, 2022 → Jul 7, 2023

NCT ID

NCT05461105

About rencofilstat, 75 mg + rencofilstat, 150mg + rencofilstat, 225 mg

rencofilstat, 75 mg + rencofilstat, 150mg + rencofilstat, 225 mg is a phase 2 stage product being developed by Hepion Pharmaceuticals for NASH With Fibrosis. The current trial status is completed. This product is registered under clinical trial identifier NCT05461105. Target conditions include NASH With Fibrosis.

What happened to similar drugs?

0 of 5 similar drugs in NASH With Fibrosis were approved

Approved (0) Terminated (1) Active (4)

🔄IVA337 + PlaceboInventivaPhase 3

🔄MGL-3196 + PlaceboMadrigal PharmaceuticalsPhase 3

🔄Resmetirom + PlaceboMadrigal PharmaceuticalsPhase 3

❌Elafibranor + PlaceboGenfitPhase 3

🔄Aramchol free acid + PlaceboGalmed PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT05461105	Phase 2	Completed	Mar 15, 2022	Jul 7, 2023	NASH With Fibrosis

Competing Products

20 competing products in NASH With Fibrosis

See all competitors

Product	Company	Stage	Hype Score
VK2809 + Placebos	Viking Therapeutics	Phase 2	32
TERN-501 + TERN-101	Terns Pharmaceuticals	Phase 2	32
TERN-101	Terns Pharmaceuticals	Phase 2	32
TERN-201	Terns Pharmaceuticals	Phase 1	26
IVA337 + IVA337 + Placebo	Inventiva	Phase 2	29
IVA337 + Placebo + Empagliflozin	Inventiva	Phase 2	29
IVA337 + Placebo	Inventiva	Phase 3	41
AZD2693	AstraZeneca	Phase 1	29
AZD4076 + Placebo	AstraZeneca	Phase 1	29
LIK066 + Placebo	Novartis	Phase 2	35
Tropifexor (LJN452) + Cenicriviroc (CVC)	Novartis	Phase 2	35
Tropifexor + Licogliflozin	Novartis	Phase 2	27
LMB763 + Placebo	Novartis	Phase 2	27
Tropifexor (LJN452) + Placebo	Novartis	Phase 2	27
TRO19622 + Placebo	Roche	Phase 2	35
SEL + SIM	Gilead Sciences	Phase 2	35
Seladelpar + Placebos	Gilead Sciences	Phase 2	27
Placebo + SIM	Gilead Sciences	Phase 2	27
Cilofexor	Gilead Sciences	Phase 1	29
Firsocostat + Fenofibrate	Gilead Sciences	Phase 1	29